on December 26, 2008
Published online before print December 26, 2008, doi: 10.1161/ATVBAHA.108.176362
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 26, 2008
Accepted on December 15, 2008
Effect of Rimonabant on the High-Triglyceride/ Low–HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat. The ADAGIO-Lipids Trial
Jean-Pierre Després *;
From the Hôpital Laval Research Centre (J.-P.D., N.A., I.L.), Québec, Canada; Queen's University (R.R.), Kingston, Canada; and sanofi-aventis R&D (G.B.), Antony, France.
* To whom correspondence should be addressed. E-mail: jean-pierre.despres{at}crhl.ulaval.ca.
Background—Rimonabant, the first selective cannabinoid type 1 (CB1) receptor antagonist, improves cardiometabolic risk factors in overweight/obese patients. ADAGIO-Lipids assessed the effect of rimonabant on cardiometabolic risk factors and intraabdominal and liver fat.
Methods and Results—803 abdominally obese patients with atherogenic dyslipidemia (increased triglycerides [TG] or reduced high-density lipoprotein–cholesterol [HDL-C]) were randomized to placebo or rimonabant 20 mg/d for 1 year. HDL-C and TG were coprimary end points. Intraabdominal (visceral) and liver fat were measured by computed tomography in a subgroup of 231 patients. In total, 73% of rimonabant- and 70% of placebo-treated patients completed the study treatment. Rimonabant 20 mg produced significantly greater changes from baseline versus placebo in HDL-C (+7.4%) and TG levels (-18%; P<0.0001), as well as low-density lipoprotein (LDL) and HDL particle sizes, apolipoprotein A1 and B, HDL2, HDL3, C-reactive protein, and adiponectin levels (all P<0.05). Rimonabant decreased abdominal subcutaneous adipose tissue (AT) cross-sectional area by 5.1% compared to placebo (P<0.005), with a greater reduction in visceral AT (-10.1% compared to placebo; P<0.0005), thereby reducing the ratio of visceral/subcutaneous AT (P<0.05). Rimonabant significantly reduced liver fat content (liver/spleen attenuation ratio; P<0.005). Systolic (-3.3 mm Hg) and diastolic (-2.4 mm Hg) blood pressure were significantly reduced with rimonabant versus placebo (P<0.0001). The safety profile of rimonabant was consistent with previous studies; gastrointestinal, nervous system, psychiatric, and general adverse events were more common with rimonabant 20 mg.
Conclusions—In abdominally obese patients with atherogenic dyslipidemia, rimonabant 20 mg significantly improved multiple cardiometabolic risk markers and induced significant reductions in both intraabdominal and liver fat.
Key words: cardiometabolic risk • dyslipidemia • intraabdominal obesity • liver fat • rimonabant
Related Article:
- ADAGIO-Lipids Gives Promises but Faces the Setbacks
- Marja-Riitta Taskinen
Arterioscler Thromb Vasc Biol 2009 29: 339-340.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
 |
|
 |
|
  V. Di Marzo, A. Verrijken, A. Hakkarainen, S. Petrosino, I. Mertens, N. Lundbom, F. Piscitelli, J. Westerbacka, A. Soro-Paavonen, I. Matias, et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects Eur. J. Endocrinol., November 1, 2009; 161(5): 715 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Weiss, L. Appelbaum, C. Schweiger, I. Matot, N. Constantini, A. Idan, N. Shussman, J. Sosna, and A. Keidar Short-Term Dynamics and Metabolic Impact of Abdominal Fat Depots After Bariatric Surgery Diabetes Care, October 1, 2009; 32(10): 1910 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-R. Taskinen ADAGIO-Lipids Gives Promises but Faces the Setbacks Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 339 - 340. [Full Text] [PDF]
|
|